Indian Price Controls To Cap Cost Of Insulin Drugs
This article was originally published in PharmAsia News
India's drug pricing authority plans to cap the price of insulin drugs to curb what it considers transfer pricing abuse. The National Pharmaceutical Pricing Authority relies on production costs used by domestic drug makers to set a retail price, but has no access to similar information from firms owned or operated outside the country. Its ceiling on the price of both injectable and cartridge insulin covers imported and domestic brands, but about 90 percent of the market is dominated by imports. (Click here for more
You may also be interested in...
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.
Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement.